STAT Flagged the Same Oregon Psilocybin Data We Did — Here's What's Actually in It
STAT's Elaine Chen flagged this back in August, and it's worth a closer look than a paywalled newsletter item allows: the first full results from Oregon's legal psilocybin services program, published in JAMA Network Open — the largest real-world dataset on legal psilocybin use that exists anywhere. Oregon Health & Science University tracked 346 people across 24 licensed service centers from November 2024 through June 2026, following each person for three months after a single session. The numbers are genuinely strong: moderate- to-severe depression symptoms fell from 42.2% of participants at baseline to 16.5% at three months; anxiety fell from 45.1% to 13.2%; PTSD symptoms fell from 48% to 16.8%. 91.5% of participants said they benefited, and 64.9% ranked the session among the ten most meaningful experiences of their life.
The safety side is exactly why Chen's "close monitoring" framing holds up: facilitators or clients reported a serious behavioral reaction in 4 of 346 sessions (1.2%), including one hospital transport, and no serious physical health events. That's a real, if small, adverse event rate in a context with none of the screening infrastructure a clinical trial would require — Oregon's centers do their own intake screening, but this is observational real-world data, not a controlled study. Worth reading next to our own trial tracker, which covers the controlled, pre-approval side of the same compound.